| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3548 | 2014 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2847 | 2019 |
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative … RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ... The lancet oncology 16 (1), 25-35, 2015 | 2102 | 2015 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1525 | 2019 |
| Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines C Schauer, C Janko, LE Munoz, Y Zhao, D Kienhöfer, B Frey, M Lell, ... Nature medicine 20 (5), 511-517, 2014 | 916 | 2014 |
| Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer MER O'Brien, TE Ciuleanu, H Tsekov, Y Shparyk, B Cuceviá, G Juhasz, ... Journal of Clinical Oncology 24 (34), 5441-5447, 2006 | 722 | 2006 |
| Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials A Lipton, K Fizazi, AT Stopeck, DH Henry, JE Brown, DA Yardley, ... European journal of cancer 48 (16), 3082-3092, 2012 | 633 | 2012 |
| Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, ... The Lancet 388 (10063), 2997-3005, 2016 | 605 | 2016 |
| Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal … JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ... Journal of Clinical Oncology 34 (5), 443-451, 2016 | 578 | 2016 |
| 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ... The Lancet Neurology 8 (10), 889-897, 2009 | 515 | 2009 |
| Host DNases prevent vascular occlusion by neutrophil extracellular traps M Jiménez-Alcázar, C Rangaswamy, R Panda, J Bitterling, YJ Simsek, ... Science 358 (6367), 1202-1206, 2017 | 509 | 2017 |
| Placebo-controlled trial of oral laquinimod for multiple sclerosis G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi New England Journal of Medicine 366 (11), 1000-1009, 2012 | 442 | 2012 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 429 | 2021 |
| Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity D Havrylyuk, B Zimenkovsky, O Vasylenko, L Zaprutko, A Gzella, R Lesyk European journal of medicinal chemistry 44 (4), 1396-1404, 2009 | 392 | 2009 |
| Медичне право України: підручник ІЯС Семен Григорович Стеценко, ВЮ Стеценко К.: Всеукраїнська асоціація видавців «Правова єдність, 2008 | 379* | 2008 |
| 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry RB Lesyk, BS Zimenkovsky Current Organic Chemistry 8 (16), 1547-1577, 2004 | 368 | 2004 |
| To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps S Boeltz, P Amini, HJ Anders, F Andrade, R Bilyy, S Chatfield, I Cichon, ... Cell Death & Differentiation 26 (3), 395-408, 2019 | 365 | 2019 |
| Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety D Havrylyuk, L Mosula, B Zimenkovsky, O Vasylenko, A Gzella, R Lesyk European Journal of Medicinal Chemistry 45 (11), 5012-5021, 2010 | 342 | 2010 |
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ... The Lancet 381 (9884), 2167-2175, 2013 | 335 | 2013 |
| European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS) J Egea, I Fabregat, YM Frapart, P Ghezzi, A Görlach, T Kietzmann, ... Redox biology 13, 94-162, 2017 | 315 | 2017 |
Roman LesykDanylo Halytsky Lviv National Medical UniversityVerified email at org.lviv.net
